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were selected for inclusion in the Lupus Impact Tracker, a PRO intended for clinical
practice use to monitor the impact of SLE on patients’ lives and well being.
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OBJECTIVES: A daily assessment of the speed of action and effectiveness of treat-
ment of a combination of paracetamol and codeine in patients suffering from
intense pain, which has progressed since less than 7 days.METHODS: Amulticen-
tre longitudinal observational prospective study carried out inmetropolitan France
using data collected by general practitionerswho agreed to participate. RESULTS:A
total of 574 patients treated by a paracetamol-codeine combination (600mg/50mg
and 400mg/20mg) were included. The severity of pain measured at inclusion using
a visual numeric scalewas 71.28. The severity of painmeasured after half a day of
treatment was 5.611.87 and 5.28  1.86 at the end of the first 24 hours of treat-
ment. A significant improvement in pain was observed from the first half-day
(p0.001). The severity of pain on the 2nd, 4th and 7th evenings was respectively
4.081.85; 2.761.76 and 1.79 1.69 On D1, 69.7% declared treatment to be effec-
tive, 61.04%were satisfiedwith their treatment and 79.26%did not observe any side
effects to the treatment. On D7, 96.15% (D3, 91.3% ) declared treatment to be effec-
tive, 87.10%were satisfiedwith their treatment and 88.96%did not observe any side
effects to the treatment. 8 out of 10 patients did not complain about side effects
related to the treatment. CONCLUSIONS: A reduction in pain within the first 12
hours showed the pertinence of treatment using a paracetamol-codeine combina-
tion. This pertinencewas confirmed by two-thirds patients who declared the treat-
ment to be effective from the 1st day, and 91% of them declared this on the 3rd day
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OBJECTIVES: The diabetic peripheral neuropathy (DPN) is the most common
chronic complication of diabetes. Neuropathic pain tends to be severe, chronic, and
has a hugely negative impact on the physical and emotional functioning, and over-
all well-being of the patient. This study was performed to evaluate the scope of
pain and quality of life among patients with painful diabetic peripheral
neuropathy.METHODS: A cross-sectional, observational study was carried out on
type 2 diabetic patients from 40 medical centers throughout Korea. The standard-
ized questionnaires such as Michigan Neuropathy Screening Instrument (MNSI),
Brief Pain Inventory-short form (BPI-sf), MOS 6-items Sleep Scale and EuroQoL
(EQ-5D) were used to diagnosis and estimate the quality of life in people with DPN.
A patient with DPN was defined as the patients who showed positive patients
medical records or neuropathic symptoms (MNSI2) and positive response on the
basic neurological examination (Monofilament test). RESULTS: Among 4,000 dia-
betic patients, 33.5% had DPN. Of those 1,338 DPN patients, 874 (65.3%) took pain
medications or had 1 worst pain scores (BPI-sf, 0-10 scales). Patients who took
pain medications or had 1 worst pain scores were 6310.6 years old (57.9% fe-
male), had diabetes for 138.0 years and DPN for 4.03.3 years. Average andWorst
Pain score were 2.92.3 and 4.93.1. Pain interference index were higher in pa-
tientswho took painmedications or had1worst pain scores (2.42.6 and 0.20.8,
respectively, P0.0001). Pain substantially interfered with general activity, mood,
walking, normal work, relationships, sleep, and enjoyment of life. These patients
reported greater sleep problems compared with DPN patients without pain. The
mean EQ-5D utility score was 0.60.2. CONCLUSIONS: This study found that pain
associated with diabetic neuropathy is a significant medical issue that has a sub-
stantial impact on the quality of life of many people with this condition.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patientswith hereditary coagulopathies inKazakhstan.METHODS: Postal and tele-
phone health survey. Questionnaires were distributed in May - August 2009. The
questionnaire contained questions on clotting factor level, number of bleeding,
number of injections of clotting factors, ways of receiving medications, number of
ambulance calls and hospitalizations, and the way of administration ofmedicines.
The patients’ education level and employment data was collected. Analysis was
performed with 2 and Student’s criteria. RESULTS: 626 completed questionnaires
were received by September, 2009. Hemophilia A was reported by 486 responders
(77.6%). 426 patients (68%) were adults. Mean age was 25.4 years. 60 patients with
hemophilia A and B (11.6%) had a level of coagulation factors lower then 1%, i.e.
they had a severe form of disease. The presence of antibodies was detected in 68
patients (11%). 87.8% of patients experienced bleeding in the last month. The me-
dian of a number of bleeding among all bled patients was 2. 84.4% of patients used
clotting factors in the last month. The median number of injections of clotting
factor VIII in patients with hemophilia A was 2 (standard frequency is 12). 7.2% of
patients called for an ambulance in a lastmonth (medium frequency of calls in last
month – 2). 7.4% of patients were hospitalized during last month (medium fre-
quency of hospitalization – 2). 564 (90.2%) of patients perform the injections of
clotting factor themselves. 12.8% of patients reported use of prophylaxis scheme of
treatment hemophilia, 70.6% of patients reported use of “on demand” scheme.
CONCLUSIONS: Results of survey showed very low rate of treatment of hemophilia
with proper prophylactic scheme (less than 13%of patients). The rate of ambulance
calls and hospitalizations is comparatively low. Themajority of patients introduce
the factors themselves.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patients with hereditary coagulopathies in Ukraine.METHODS: Postal health sur-
vey. Questionnaires were distributed in May - August 2009. The questionnaire
contained questions on clotting factor level, number of bleeding, injections of clot-
ting factors, ways of receiving medications, number of ambulance calls and hospi-
talizations, and the way of administration of medicines. Analysis of experimental
data was performed with such statistical parameters as 2 and Student’s criteria.
RESULTS: 154 completed questionnaires were received by September, 2009. Hemo-
philia Awas reported by 103 responders (67%). 126 (81.8%) patientswere adults. The
detection of a level of coagulation factors during last year was done in 50 (40.4%)
patients with hemophilia A and B. 24 (19.4%) patients with hemophilia A and B had
a level of coagulation factors lower then 1%, i.e. they had a severe form of disease.
The presence of antibodies was detected in 27 patients (17.5%). 80.6% of patients
experienced bleeding during the last month (median - 4). 51.4% of patients with
hemophilia A used clotting factor VIII during last month. The median number of
injections of clotting factor VIII in patients with hemophilia A was 4 (standard
frequency is 12). 36.4% of patients called for an ambulance during last month
(medium frequency – 1). 49.3% of patients were hospitalized during last month
(medium frequency – 1). Only 23 (15%) of patients performed the injections of
clotting factor themselves. Only 1.3% of patients reported use of prophylaxis
scheme of treatment hemophilia, 85.7% of patients reported use of “on demand”
scheme. CONCLUSIONS: Results of survey showed very low rate of treatment of
hemophilia with proper prophylactic scheme (about than 1.3% of patients). The
rate of ambulance calls and hospitalizations is extremely high. The majority of
patients introduce the factors in hospitals.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patientswith hereditary coagulopathies inKazakhstan.METHODS: Postal and tele-
phone health survey. Questionnaires were distributed in May - August 2009. The
questionnaire contained questions on clotting factor level and presence of anti-
bodies to it, number of bleeding in last month, number of injections of clotting
factors per month, names of used medications, ways of receiving medications,
number of ambulance calls and hospitalizations, and the way of administration of
medicines (self-administration of administration at a ambulatory/hospital). The
patients’ education level and employment datawas collected. Health-related qual-
ity of life was assessed with self-administrated validated version of Russian ver-
sion of Euroqol-5D questionnaire. Comparisonwasmadewith health-related qual-
ity of life of Russian patients data (P.Vorobeyv et. al., 2008, data of 1003 patientswas
used in analyses). RESULTS: 626 completed questionnaires were received by Sep-
tember, 2009. Health-related quality of life was assessed for patients older than 11
years (n 514). More than half of patients reported problems within each of EQ-5D
dimensions of health. Thus 63.9% of patients reported of problems (moderate and
severe) with mobility (63.9% of Russian patients, p0.05); 65.2% of patients in-
formed of difficulties with self-care (35.5% of Russian patients, p0.05); 70.1% of
patients had difficultieswith usual activity (61.9% of Russian patients, p0.05); 74%
of patients reported of presence of pain or discomfort (78.4% of Russian patients,
p0.05); 27.3% of patients had an anxiety or depression (54.2% of Russian patients,
p0.05). The average value of quality of life evaluated with visual-analog scale
(VAS) was 0.53 (SD 0.18), median - 50. CONCLUSIONS: Results of the study shown
high rate of problemswithmobility, usual activity and high rate of pain/discomfort
and low rate of problem with anxiety/depression.
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OBJECTIVES: To assess epidemiology of anemia cased by chronic renal failure in
patients on dialysis and patient’s quality of life. METHODS: Health survey of pa-
tients in dialysis departments of 23 regions. About 1400 questionnaires were dis-
tributed in May - June 2010. The form contained following questions: personal
information (name, age, patients’ education and employment), medical data (di-
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agnosis, duration of disease, clinical and laboratory symptoms, procedures of di-
alysis and antianemic therapy). Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. RESULTS: 1395
completed questionnaires were received by September, 2010. Mean age was 42
years. 45% patients reported chronic glomerulonephritis as a main reason of
chronic renal failure, 22% - chronic pyelonephritis, 10% - diabetes, 8% - polycystic
kidney disease, other diseases – 1,5%. Average level of hemoglobin was 10716.2
g/l. 80% of patients reported that they got 12-14 procedures of dialysis during last
month. The average length of one procedure was 4-5 hours just for 17% of patients,
in other cases (80%) length of dialysis was shorter. Analysis of antianemic therapy
has shown that 85% got erytropoetins and 70% - iron supplements. More than half
of patients reported problems within each of EQ-5D dimensions of health. Thus
42.5% of patients reported problems withmobility, 20% - difficulties with self-care;
58.7% - difficulties with usual activities; 67% - reported about pain or discomfort;
47% - reported about an anxiety or depression. The average value of quality of life
evaluated with visual-analog scale (VAS) was 0.59 (SD 0.17), median – 0.6.
CONCLUSIONS:Analyses of quality of life have demonstrated high rate of problem
with usual activity and pain and discomfort and low rate of problem with self-
service.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patients with hereditary coagulopathies in Ukraine.METHODS: Postal health sur-
vey. Questionnaires were distributed in May - August 2009. Health-related quality
of life was assessedwith self-administrated validated version of Russian version of
Euroqol-5D questionnaire. Comparison was made with data about health-related
quality of life of Russian patients (P.Vorobeyv et. al., 2008, data of 1003 patients was
used in analyses). Analysis of experimental data was performed with 2 criteria.
RESULTS: 154 completed questionnaires were received by September, 2009.
Health-related quality of lifewas assessed for patients older than 11 years (n 142).
More than half of patients reported problems within each of EQ-5D dimensions of
health. Thus 88.8% of patients reported of problems (moderate and severe) with
mobility (63.9% of Russian patients, p0.05), 57.7% of patients inform of difficulties
with self-care (35.5% of Russian patients, p0.05); 81% of patients had difficulties
with usual activity (61.9% of Russian patients, p0.05); 90.9% of patients reported of
presence of pain/discomfort (78.9% of Russian patients, p0.05); 60.5% of patients
had an anxiety or depression (54.2% of Russian patients, p0.05). The average value
of quality of life according to visual-analog scalewas 0.44 (SD 0.22). CONCLUSIONS:
The study of quality of life in patients with hereditary coagulopathies was per-
formed for the first time in Ukraine. Results of the study shown high rate of prob-
lems all aspects of health-related quality of life. Ukraine patients with hemophilia
have worse quality of life than Russian patients.
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OBJECTIVES: The fight against pain, which represents a public health challenge
and a criteria of the quality and development of a health system, above all aspires
tomeet objectives of humanity, ethics and human dignity. Physical pain andmen-
tal suffering experienced across all age groups renders those affected by illness
even more vulnerable. Pain causes incapacity, handicap and considerable deterio-
ration in the quality of life. Fighting against pain meets a legitimate expectation of
every person. METHODS: To assess the quality of life in patients suffering from
intense pain which has progressed since less than 7 days treated by a combination
of paracetamol and codeine. Amulti-centre longitudinal observational prospective
study carried out in metropolitan France using data collected by general practitio-
ners who agreed to participate. RESULTS: 574 patients treated by a paracetamol-
codeine combination (600mg/50mg and 400mg/20mg) were included; at inclusion
the quality of life assessed using SF-12was affected asmuch in terms of themental
component (41.83  7.92) as the physical component (35.88  11.68) – the norm of
the scores for each component is equal to 50 – on D7, the quality of life assessed in
a similarmanner using SF-12 was 43.31 9.89 for themental component and 40.93
7.92 for the physical component. A statistically significant improvementwas noted
for each of the 2 mental (p0.0091) and physical (p0.0001) components between
the first day of treatment and the 7th day. CONCLUSIONS: The improvement in
quality of life observed directly through SF-12 was also confirmed by patient satis-
faction: from the first day, 61% of patients declared themselves to be satisfied. On
the 7th day of treatment, 87.10% were satisfied with their treatment.
PSY45
CHARACTERISTICS OF CAREGIVERS AND THEIR EXPERIENCE ASSOCIATED
WITH CONGENITAL HEMOPHILIA OF INHIBITOR PATIENTS
Wisniewski T1, Petrilla AA2, DeKoeven M2, Lee WC2, Cooper DL1, Holot N1,
von Mackensen S3
1Novo Nordisk, Inc., Princeton, NJ, USA, 2IMS Health, Falls Church, VA, USA, 3University
Medical Centre Hamburg-Eppendorf, Hamburg, Germany
OBJECTIVES: Congenital hemophilia is a chronic disease diagnosed early in life in
severe cases. Development of alloantibody inhibitors to exposure to replacement
factor VIII and IX concentrates is the most serious treatment complication among
patients. It is estimated that 900-1,200 patients have congenital hemophilia with
inhibitors (CHwI) in theUnited States (US). Limited research exists to document the
experience of their caregivers.METHODS: As part of a cross-sectional survey eval-
uating preservation of joint health and quality of life among CHwI patients in the
US, caregivers’ experience was assessed via the HAEMO-QoL instrument, contain-
ing an open-ended question capturing caregivers’ burden. Responses were as-
sessed for trends and consolidated into categories. Descriptive analyses were em-
ployed to evaluate caregivers’ demographic characteristics and their burden with
the disease. RESULTS: Questionnaires were received from 60 caregivers. Mean age
of patients under care was 10.6 years (SD10.3). 91.7% of patients under care had
Hemophilia A and 68.3% had high-titer inhibitors. Unemployment as a result of
caregiver responsibilities was reported by 28.1%. 31.7% reported having health
insurance with a lifetime cap. Among these, 73.7% were “somewhat” to “very con-
cerned” about reaching the cap. Among 55 HAEMO-QoL respondents 26.3% were
“considerably” to “very much so” bothered by the patient’s disease. A total of 159
open-ended responses were provided by 51 caregivers concerning their experience
about living with hemophilia and its treatment: 22.6% highlighted emotional
stress, 15.1% emphasized financial burden includingwork time, 12.0% involved lost
time excluding work, and 11.3% involved medical management issues.
CONCLUSIONS: One quarter of caregivers were “considerably” to “very much”
bothered by the patient’s condition. They reported emotional stress and financial
burden as negative experiences dealing with hemophilia and its treatment. Medi-
calmanagement is also an area of concern. A caregiver’s negative experiencemight
impact children’s HRQoL, which should be analyzed in future research.
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OBJECTIVES: The impact of lupus on patients’ everyday lives is important to un-
derstand. We therefore investigated the perceptions of lupus patients on disease
symptoms and coping strategies. METHODS: Participants (USA and Europe) com-
pleted a patient-led Internet-based questionnaire between April and May 2009.
RESULTS: 914 respondents reported having lupus (95% female, 80% 20–50 years of
age). Themost common lupus symptoms reportedwere fatigue (92%) and arthritis,
muscle pain/weakness or tendinitis (89%). Antimalarials were themost commonly
used lupus treatment (53%), followed by corticosteroids (51%). Less than half of the
respondents were satisfied/very satisfied with their current treatment (49%). Ap-
proximately one-third of respondents stated that lupus had a highly significant
effect on their careers (37%), on their physical well-being (34%) and on everyday
things (30%). Furthermore, approximately one-fifth of respondents felt that lupus
had a highly significant effect on their social life (23%) and mental health (20%),
while 11% reported it had a highly significant effect on their relationship with their
family. Most patients reported talking to family (93%) and friends (89%) about lupus
or sharing with them they had lupus (97% and 95%, respectively); 79% reported
talking to others with lupus. 77% reported it was ‘easy/very easy’ to talk to their
doctors about their symptoms. The most difficult symptoms to explain were de-
pression (45%) and CNS problems (34%). The most helpful forms of support were
understanding from family and friends (73%), ability to speak with healthcare pro-
fessionals (63%), and being connected to other lupus patients via the Internet (50%).
CONCLUSIONS: Lupus impacts greatly on patient’s everyday lives with the most
common symptom reported being fatigue. Many patients remain unsatisfied with
their treatment. Communicationwith familymembers, friends, healthcare profes-
sionals and other lupus patients are important strategies to facilitate coping with
lupus symptoms.
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OBJECTIVES: Efficacious medical or behavioral weight-loss programs are not rou-
tinely covered by insurance. Understanding how patients value weight loss inter-
ventions by assessing their willingness to pay (WTP) is critical to translating find-
ings from effectiveness trials into practice. Upon completion of a randomized
clinical trial comparing an in-person behavioral intervention to a phone/email/
web-based intervention for weight-loss, we studied participants’ WTP and charac-
teristics associated with WTP for continuing these programs. METHODS: POWER
Hopkins is an NHLBI-funded 24-month randomized clinical trial of weight loss
comparing in-person vs. call center directed coaching interventions plus web-
based education and tracking support. At the end-of-study visit, we interviewed
participants and used double bound dichotomous-choice to assess their WTP. Us-
ing linear regression, we examined baseline characteristics (age, sex, income, race,
education, and BMI) associated with WTP. RESULTS: Of the 234 adults completing
the trial to date, 206 (88%) reported on WTP. Mean age was 57 years, 61% were
women, 56.3% were White, mean BMI at baseline (2 years earlier) was 36.4 kg/m2,
33% had graduate or professional degrees, 61% had annual family income
$75,000. Participants thought their intervention was worth $70.9 (95%CI 60.3-
A67V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
